• Earlier this month, BioCryst Pharmaceuticals reported third quarter revenue of US$159.4 million and net income of US$12.9 million, alongside raising its full year 2025 global net ORLADEYO revenue guidance and projecting a profitable year.
• This marks a turnaround from prior losses and highlights the impact of growing ORLADEYO adoption, with analyst attention on the company’s new pediatric HAE data as a potential market expansion lever.
• We’ll explore how BioCryst’s raised revenue outlook and pediatric ORLADEYO trial results could influence its investment narrative and future growth potential.

Find companies with promising cash flow potential yet trading below their fair value.

BioCryst Pharmaceuticals Investment Narrative Recap

To be a shareholder in BioCryst Pharmaceuticals, you need to believe in the long-term prospects of ORLADEYO driving consistent revenue and profit growth, and that an expansion into the pediatric hereditary angioedema (HAE) market will offset single-product dependence. The latest positive APeX-P pediatric trial results and the ongoing FDA review could directly impact the biggest near-term catalyst: potential approval and launch of ORLADEYO granules for children, a key avenue for new market expansion. The largest, ongoing risk remains BioCryst’s reliance on ORLADEYO, with future revenue concentration heightened by increasing HAE competition.

The November 6 announcement of strong pediatric ORLADEYO data and the upcoming FDA decision date make the company’s recent revision of its 2025 global net ORLADEYO revenue guidance to US$590 million to US$600 million highly relevant. Elevated expectations now hinge on both continued ORLADEYO adoption and regulatory success in pediatrics, putting extra weight on FDA outcomes and ongoing market uptake to deliver on future growth targets.

By contrast, investors should also be aware that if ORLADEYO’s pediatric approval is delayed or market uptake disappoints, the company’s high product concentration risk could...

BioCryst Pharmaceuticals' narrative projects $777.6 million revenue and $212.3 million earnings by 2028. This requires 11.7% yearly revenue growth and a $248 million increase in earnings from -$35.7 million today.

Uncover how BioCryst Pharmaceuticals' forecasts yield a $19.73 fair value, a 179% upside to its current price.

Exploring Other Perspectives

Fair value estimates from 5 Simply Wall St Community members range from as low as US$3.53 to as high as US$69.04 per share. While some see upside or caution in those scenarios, BioCryst’s opportunity now pivots on expanding ORLADEYO’s reach in the pediatric HAE market, reminding you that market participants often interpret the same catalyst through a wide lens of possible outcomes.

Explore 5 other fair value estimates on BioCryst Pharmaceuticals - why the stock might be worth over 9x more than the current price!

Build Your Own BioCryst Pharmaceuticals Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your BioCryst Pharmaceuticals research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free BioCryst Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate BioCryst Pharmaceuticals' overall financial health at a glance.

Want Some Alternatives?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.
• We've found 16 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.